Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication

Area of Science:

• Gastroenterology
• Infectious Diseases
• Pharmacology

Background:

• Helicobacter pylori (H. pylori) infection is a common cause of peptic ulcers and gastric cancer.
• Effective eradication therapies are crucial for preventing H. pylori-related complications.
• Lansoprazole-based regimens, including sequential and concomitant therapies, are widely used for H. pylori eradication.

Purpose of the Study:

• To compare the efficacy of first-line lansoprazole-based sequential therapy versus concomitant therapy for H. pylori eradication.
• To evaluate patient tolerance and compliance with both treatment regimens.
• To investigate the impact of antibiotic resistance on treatment outcomes.

Main Methods:

• A prospective study involving 169 patients with H. pylori infection.
• Random assignment to either sequential therapy or concomitant therapy groups.
• Efficacy assessed by endoscopy or urea breath test at least 12 weeks post-treatment.

Main Results:

• Comparable H. pylori eradication rates were observed between sequential (80.0% ITT, 85.3% PP) and concomitant (88.1% ITT, 94.6% PP) therapy groups.
• Both regimens demonstrated good tolerance and compliance.
• Dual antibiotic resistance impacted sequential therapy efficacy but was not an independent predictor of treatment outcome.

Conclusions:

• First-line lansoprazole-based sequential and concomitant therapies are equally effective for H. pylori eradication.
• Both treatment strategies are well-tolerated and suitable for clinical practice.
• Further research may explore strategies to overcome antibiotic resistance in H. pylori treatment.